Skip to main content
Journal cover image

Cardiovascular and Limb Outcomes in Patients With Diabetes and Peripheral Artery Disease: The EUCLID Trial.

Publication ,  Journal Article
Low Wang, CC; Blomster, JI; Heizer, G; Berger, JS; Baumgartner, I; Fowkes, FGR; Held, P; Katona, BG; Norgren, L; Jones, WS; Lopes, RD ...
Published in: J Am Coll Cardiol
December 25, 2018

BACKGROUND: Diabetes confers an increased risk for atherosclerotic cardiovascular disease, but less is known about the independent risk diabetes confers on major cardiovascular and limb events in patients with symptomatic peripheral artery disease (PAD) on contemporary management. OBJECTIVES: The authors sought to assess the risk of cardiovascular and limb events in patients with PAD and diabetes as compared with those with PAD alone. METHODS: In the EUCLID (Examining Use of Ticagrelor in Peripheral Artery Disease) trial, 13,885 patients with symptomatic PAD were evaluated with a primary endpoint of an adjudicated composite of major adverse cardiovascular events (MACE) (cardiovascular death, myocardial infarction, ischemic stroke) followed over a median of ∼30 months. The diabetes subgroup was analyzed compared with the subgroup without diabetes, and further examined for diabetes-specific factors such as glycosylated hemoglobin (HbA1c) that might affect risk for major cardiovascular and limb outcomes. RESULTS: A total of 5,345 patients (38.5%) had diabetes; the majority (n = 5,134 [96.1%]) had type 2 diabetes. The primary endpoint occurred in 15.9% of patients with PAD and diabetes as compared with 10.4% of those without diabetes (absolute risk difference 5.5%; adjusted hazard ratio: 1.56; 95% confidence interval [CI]: 1.41 to 1.72; p < 0.001). Every 1% increase in HbA1c was associated with a 14.2% increased relative risk for MACE (95% CI: 1.09 to 1.20; p < 0.0001). CONCLUSIONS: Patients with PAD and diabetes are at high risk for cardiovascular and limb ischemic events, even on contemporary therapies. Every 1% increase in HbA1c was associated with a 14.2% increased relative risk for MACE (95% CI: 1.09 to 1.20; p < 0.0001). (A Study Comparing Cardiovascular Effects of Ticagrelor and Clopidogrel in Patients With Peripheral Artery Disease [EUCLID]; NCT01732822).

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Am Coll Cardiol

DOI

EISSN

1558-3597

Publication Date

December 25, 2018

Volume

72

Issue

25

Start / End Page

3274 / 3284

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Ticagrelor
  • Platelet Aggregation Inhibitors
  • Peripheral Arterial Disease
  • Middle Aged
  • Male
  • Lower Extremity
  • Ischemia
  • Humans
  • Female
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Low Wang, C. C., Blomster, J. I., Heizer, G., Berger, J. S., Baumgartner, I., Fowkes, F. G. R., … EUCLID Trial Executive Committee and Investigators. (2018). Cardiovascular and Limb Outcomes in Patients With Diabetes and Peripheral Artery Disease: The EUCLID Trial. J Am Coll Cardiol, 72(25), 3274–3284. https://doi.org/10.1016/j.jacc.2018.09.078
Low Wang, Cecilia C., Juuso I. Blomster, Gretchen Heizer, Jeffrey S. Berger, Iris Baumgartner, F Gerry R. Fowkes, Peter Held, et al. “Cardiovascular and Limb Outcomes in Patients With Diabetes and Peripheral Artery Disease: The EUCLID Trial.J Am Coll Cardiol 72, no. 25 (December 25, 2018): 3274–84. https://doi.org/10.1016/j.jacc.2018.09.078.
Low Wang CC, Blomster JI, Heizer G, Berger JS, Baumgartner I, Fowkes FGR, et al. Cardiovascular and Limb Outcomes in Patients With Diabetes and Peripheral Artery Disease: The EUCLID Trial. J Am Coll Cardiol. 2018 Dec 25;72(25):3274–84.
Low Wang, Cecilia C., et al. “Cardiovascular and Limb Outcomes in Patients With Diabetes and Peripheral Artery Disease: The EUCLID Trial.J Am Coll Cardiol, vol. 72, no. 25, Dec. 2018, pp. 3274–84. Pubmed, doi:10.1016/j.jacc.2018.09.078.
Low Wang CC, Blomster JI, Heizer G, Berger JS, Baumgartner I, Fowkes FGR, Held P, Katona BG, Norgren L, Jones WS, Lopes RD, Olin JW, Rockhold FW, Mahaffey KW, Patel MR, Hiatt WR, EUCLID Trial Executive Committee and Investigators. Cardiovascular and Limb Outcomes in Patients With Diabetes and Peripheral Artery Disease: The EUCLID Trial. J Am Coll Cardiol. 2018 Dec 25;72(25):3274–3284.
Journal cover image

Published In

J Am Coll Cardiol

DOI

EISSN

1558-3597

Publication Date

December 25, 2018

Volume

72

Issue

25

Start / End Page

3274 / 3284

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Ticagrelor
  • Platelet Aggregation Inhibitors
  • Peripheral Arterial Disease
  • Middle Aged
  • Male
  • Lower Extremity
  • Ischemia
  • Humans
  • Female